H.C. Wainwright raised the firm’s price target on Unicycive Therapeutics (UNCY) to $4 from $2.50 and keeps a Buy rating on the shares following the Q3 report.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UNCY:
- Unicycive Therapeutics files $100M mixed securities shelf
- Unicycive Therapeutics reports Q3 EPS (13c), consensus (15c)
- Unicycive Therapeutics expects cash to fund operations into 2026
- Unicycive Therapeutics announces U.S. FDA acceptane for NDA for OLC
- UNCY Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue